Research Article
Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses
Figure 4
Wog prevented TAC-induced cardiac hypertrophy and dysfunction in vivo. (a, b) Echocardiographic data showed the effects of Wog on cardiac hypertrophy induced by TAC. EF: ejection fraction; FS: fractional shortening (); (c) representative M-mode echocardiograms from sham and TAC mice with vehicle or Wog; (d–f) histological staining of H&E and WGA of heart sections showed the inhibitory effect of Wog on cardiac hypertrophy after TAC surgery (magnification: ×200, scale bar: 20 μm). Quantitative analysis of cardiomyocyte cross-sectional area (); (g) representative hearts of mice that underwent sham or TAC surgery, followed by single intragastric administration of Wog (10 mg/kg/day) for 8 weeks; (h) quantitative analysis of the heart weight/body weight (HW/BW) ratio (); (i–k) mRNA expressions for Anp, Bnp, and Myhc-β determined by qRT-PCR (). , , and compared to sham; , , and compared to TAC.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |
(i) |
(j) |
(k) |